October 2024- Precision Medicine Group (Precision) announced the appointment of Margaret Keegan as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Ms. Keegan succeeds Mark Clein, who is assuming the role of Executive Chairman. Mr. Clein co-founded Precision in 2012 as CEO and, together with co-founder Ethan Leder, purpose-built Precision to capitalize on the scientific and technological innovations that are transforming drug development and enabling widespread access to new, breakthrough therapies. Mr. Leder formerly served as Executive Chairman and will remain a member of the Board of Directors.
“Together, we supported the development and launch of hundreds of therapies for some of the most intractable and devastating diseases and provided life science companies the insights, tools, and resources to navigate a complex and ever-evolving global healthcare industry. In Margaret Keegan, we have identified a leader with the vision, experience, and acumen to architect the next chapter. Ethan and I look forward to working with her to further deliver on our purpose for our clients, employees, and the patients they serve.” said Mark Clein, Co-founder and Executive Chairman of Precision.
Also Read : Anthony Hilliard announced as acting CEO of LLUH hospitals
Margaret Keegan, Chief Executive Officer, commented, “In many ways, our industry is at a similar inflection point now, as we assimilate innovations in technology and artificial intelligence and respond to new regulations and shifting macroeconomic conditions. This introduces a tremendous opportunity for Precision to advance from being the first mover in precision medicine to being the global expert in drug development and commercialization. I am thrilled to be joining Precision at this exciting point in the company’s rapid development and look forward to leading this outstanding team of professionals.”
“Our selection of Margaret as the next CEO of Precision is the result of a long-term succession planning process. Margaret is a passionate leader, with extensive and proven life sciences industry experience. She has a deep commitment to our foundational principles, with a focus on our patient-centric and client-first approach. Also, the Board is confident in her ability to grow and scale Precision as a complete development partner for our biopharmaceutical customers, from clinical R&D through commercialization,” said Dr. John Hubbard, Chairman of the Precision Board of Directors.
